Latest News

Colleen E. Annesley, MD
Colleen E. Annesley, MD, on Working to Mitigate Inferior Cell Persistence With Manufactured T-APCs

December 11th 2023

The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed complete data from the PLAT-03 feasibility trial assessing SCRI-CAR19 and CD19t T-APCs in B-ALL.

John F. DiPersio, MD, PhD, Division of Oncology, Washington University School of Medicine
CRISPR/Cas9 Edited Allograft Eases AEs of Maintenance Therapy for AML

December 10th 2023

CRISPR/Cas9 Cell Therapy Increases Hemoglobin in Transfusion-Dependent β-Thalassemia Across HBB Genotypes
CRISPR/Cas9 Cell Therapy Increases Hemoglobin in Transfusion-Dependent β-Thalassemia Across HBB Genotypes

December 10th 2023

Dr. med. Veit Bücklein
Dr. med. Veit Bücklein, on Investigating Sex Differences on CAR T Outcomes in Large B-Cell Lymphoma

December 10th 2023

Fabian Müller, MD, of Bavarian Cancer Research Institute and Friedrich-Alexander University of Erlangen-Nuremberg
CAR T Cells Highly Effective for Autoimmune Disorders

December 10th 2023

Video Interviews

Conference Coverage

View All
Colleen E. Annesley, MD
Colleen E. Annesley, MD, on Working to Mitigate Inferior Cell Persistence With Manufactured T-APCs

December 11th 2023

John F. DiPersio, MD, PhD, Division of Oncology, Washington University School of Medicine
CRISPR/Cas9 Edited Allograft Eases AEs of Maintenance Therapy for AML

December 10th 2023

CRISPR/Cas9 Cell Therapy Increases Hemoglobin in Transfusion-Dependent β-Thalassemia Across HBB Genotypes
CRISPR/Cas9 Cell Therapy Increases Hemoglobin in Transfusion-Dependent β-Thalassemia Across HBB Genotypes

December 10th 2023

Dr. med. Veit Bücklein
Dr. med. Veit Bücklein, on Investigating Sex Differences on CAR T Outcomes in Large B-Cell Lymphoma

December 10th 2023

All News

© 2023 MJH Life Sciences

All rights reserved.